ALNYLAM PHARMACEUTICALS, INC.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical enterprise focused on discovering and developing novel medicines utilizing ribonucleic acid interference (RNAi) to silence disease-causing genes. The company's portfolio features commercial products such as AMVUTTRA and ONPATTRO for transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1, alongside collaborator-marketed therapies Leqvio for hypercholesterolemia and Qfitlia for hemophilia A and B. Its therapeutic solutions are designed to treat patients suffering from rare genetic ailments as well as more prevalent cardiovascular conditions.

Operating on an international scale, the organization maintains more than 20 clinical-stage research programs across multiple medical indications. Its marketed therapies have obtained regulatory clearances and distribution reach across numerous territories, including the United States, the European Union, the United Kingdom, Japan, Brazil, and China, with partner-marketed Leqvio commercialized in 89 countries worldwide. The provided excerpt does not disclose the location of the company's corporate headquarters.

Summary of the business section of Alnylam Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed approximately 2,500 full-time employees, of whom approximately 1,945 were employed in the U.S.”